Of these, promoter CpG methylation was found to inactivate RSPO1, RSPO2 and RSPO3 in acute lymphocytic leukemia, CRC, and cholangiocarcinoma, respectively 16, 28, 29. This evidence concerns the gene RSPO2 and colorectal carcinoma.